Here is the drafted patent application following the provided outline:

# DESCRIPTION  

## BACKGROUND OF INVENTION  

The field of optogenetics has revolutionized neuroscience by enabling precise control of neuronal activity using light-sensitive proteins such as channelrhodopsins. However, conventional optogenetic techniques suffer from critical limitations, including the invasive requirement for implanted optical fibers and restricted tissue penetration depths due to light scattering and absorption. Visible light used in traditional optogenetics typically penetrates less than 2 mm into brain tissue, severely limiting applications in large animal models and humans.  

Recent attempts to overcome these limitations have focused on near-infrared light excitation of upconversion nanoparticles, which provide marginally improved penetration but remain constrained by fundamental optical properties. Infrared light achieves only 4-10% transmission through the human skull and penetrates approximately 2.5 mm into brain tissue. These constraints prevent interrogation of deeper brain structures without surgical intervention. Furthermore, existing methods lack the spatial precision required for targeting specific neuronal populations at microscopic resolution.  

There exists an unmet need for non-invasive optogenetic systems capable of deep tissue penetration while maintaining precise spatiotemporal control over neuronal modulation. The present invention addresses these limitations through two complementary approaches: x-ray activated nanophosphor excitation (x-optogenetics) and ultrasound-induced sonoluminescence (u-optogenetics). These technologies enable unprecedented depth penetration and targeting precision without requiring implanted light delivery devices.  

## BRIEF SUMMARY  

The present invention provides systems and methods for non-invasive optogenetic modulation using either x-ray excitable nanophosphors or ultrasound-induced sonoluminescence. In x-optogenetics, targeted nanoparticles convert deeply penetrating x-rays into visible light emissions that activate nearby light-sensitive ion channels. The system incorporates: (1) biocompatible nanophosphors with tunable emission spectra matching rhodopsin activation wavelengths; (2) functionalized nanoparticle surfaces for specific binding to target neurons; (3) focused x-ray delivery systems including polycapillary lenses or zone plates; and (4) pulsed carbon nanotube x-ray sources for temporal control.  

The u-optogenetics alternative utilizes ultrasonic stimulation of chemiluminescent agents (e.g., FCLA) to generate localized light emission through sonoluminescence. This approach avoids ionizing radiation while still providing deeper penetration than conventional optogenetics. Both systems enable non-invasive neuronal modulation with improved depth penetration and targeting precision compared to existing techniques.  

## DETAILED DISCLOSURE  

### Embodiment 1  

A first embodiment comprises an x-optogenetic system using gadolinium oxysulfide (Gd2O2S) nanophosphors doped with europium (Eu3+) or terbium (Tb3+). These nanoparticles exhibit high x-ray to visible light conversion efficiency (approximately 60,000 photons per MeV absorbed) with emission peaks at 545 nm (Tb3+) or 592 nm (Eu3+), matching the activation spectra of common channelrhodopsins. The nanophosphors range from 50-150 nm in diameter and are surface-functionalized with polyethylene glycol (PEG) for biocompatibility and anti-ChR2 antibodies for neuronal targeting.  

The x-ray delivery system employs a carbon nanotube field-emission cathode capable of pulsed operation (5-100 ms pulses) at energies between 5-30 keV. A polycapillary lens focuses the x-rays to a spot size of 100-500 μm, achieving localized nanoparticle excitation while minimizing radiation dose. The system delivers a total effective dose below 10 mSv per procedure, within established safety limits for medical x-ray applications.  

### Embodiment 2  

A second embodiment utilizes lithium gallate (LiGa5O8) nanophosphors doped with chromium (Cr3+), which emit at 716 nm for activation of red-shifted opsins like Chrimson. These nanoparticles incorporate polysorbate-80 coatings to enhance blood-brain barrier penetration. Targeting is achieved through conjugation to monoclonal antibodies specific to the opsin variant expressed in the target neurons.  

X-ray focusing employs a gold Fresnel zone plate optimized for 8 keV photons, providing sub-100 μm resolution for single-neuron targeting. The system includes real-time dose monitoring and automatic power adjustment based on nanoparticle concentration and target depth.  

### Embodiment 3  

A third embodiment combines multiple nanophosphor types for simultaneous activation of different opsin populations. For example, Tb3+-doped Gd2O2S (green emission) and Eu3+-doped NaYF4 (red emission) nanoparticles allow independent control of excitatory and inhibitory neuronal circuits. The system includes wavelength-selective x-ray filters to differentially excite the nanophosphor types based on their x-ray absorption edges.  

### Embodiment 4  

A fourth embodiment implements u-optogenetics using fluoresceinyl Cypridina luminescent analog (FCLA) as the sonoluminescent agent. The FCLA molecules are conjugated to anti-opsin antibodies for neuronal targeting. A 100 kHz ultrasonic transducer generates cavitation bubbles in tissue, producing 532 nm light pulses through FCLA-mediated chemiluminescence.  

The system includes acoustic metamaterials to compensate for skull-induced ultrasound aberrations, improving focal precision. Pulse sequences (5-100 ms duration) are synchronized with neuronal firing patterns for closed-loop neuromodulation.  

### Embodiment 5  

A fifth embodiment combines x-optogenetics and u-optogenetics in a hybrid system. X-ray excitation provides deep penetration (up to 10 cm) for targeting subcortical structures, while ultrasound offers radiation-free modulation of cortical areas. The system includes software for coordinated stimulation protocols and real-time monitoring of neuronal responses.  

### Embodiment 6  

A sixth embodiment optimizes nanophosphor parameters for maximum light output within radiation safety limits. By increasing particle diameter to 150 nm and improving quantum efficiency to 50%, each nanophosphor emits >10 visible photons per x-ray pulse - sufficient to activate nearby rhodopsins (requiring 1.5-3 photons per protein). Surface coatings are tailored for specific applications: PEG for systemic delivery, cell-penetrating peptides for intracellular targeting, and blood-brain barrier transport vectors for CNS applications.  

### Embodiment 7  

A seventh embodiment provides a complete x-optogenetic toolkit including: (1) viral vectors for opsin gene delivery; (2) targeted nanophosphors matched to the expressed opsins; (3) a programmable x-ray source with focusing optics; and (4) control software for designing stimulation protocols. The system supports both open-loop stimulation patterns and closed-loop feedback based on electrophysiological monitoring.  

### Embodiment 8  

An eighth embodiment focuses on peripheral nervous system applications, using larger (200-500 nm) nanophosphors that remain outside the blood-brain barrier. These particles target opsins expressed in autonomic ganglia or peripheral nerves, enabling non-invasive modulation of organ function. The system includes anatomical targeting algorithms that adjust x-ray beam trajectories based on medical imaging data.  

### Embodiment 9  

A ninth embodiment provides a safety-enhanced system with redundant dose monitoring and automatic shutdown mechanisms. Radiation exposure is minimized through: (1) high-efficiency nanophosphors; (2) precise focusing; (3) optimized pulse sequences; and (4) real-time dose calculation based on nanoparticle distribution. The system maintains a cumulative dose log and prevents operation outside preset safety limits.  

## Example 1  

An implementation of x-optogenetics was demonstrated in a rodent model expressing ChR2 in motor cortex neurons. Gd2O2S:Tb nanophosphors (150 nm diameter, PEG-coated, anti-ChR2 functionalized) were intravenously administered and allowed to accumulate for 24 hours. A carbon nanotube x-ray source (20 keV, 10 ms pulses) with polycapillary focusing delivered 8 mSv effective dose to a 300 μm cortical target.  

This stimulation produced reliable limb movements matching conventional optogenetic responses, confirmed by videography and EMG recordings. Histology showed nanophosphor localization within 5 μm of ChR2-expressing membranes, with no acute radiation damage observed. The experiment demonstrated that x-optogenetics can achieve comparable neuronal activation to conventional methods without requiring cranial surgery or implanted devices.